Header Logo

STEVEN I SHERMAN

TitleProfessor
InstitutionMD Anderson
DepartmentEndocrine Neoplasia & HD
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, Cabanillas M, Hu M, Castellanos LE, Amini B, Meric-Bernstam F, Shen T, Wu J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol. 2024 Mar 04; 8(1):62. PMID: 38438731; PMCID: PMC10912412.
      Citations:    
    2. Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles D, Williamson D, Levytskyy R, Oliver JW, Keam B, Brose M, Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytskyy R, Oliver J, Keam B, Brose MS. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359. PMID: 38062732; PMCID: PMC10951569.
      Citations:    Fields:    Translation:Humans
    3. Murray S, Subbiah V, Sherman SI, P?loquin S, Sireci A, Groh? C, Bubach P, Lazure P. Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study. Thyroid Res. 2023 Aug 14; 16(1):22. PMID: 37574538; PMCID: PMC10424354.
      Citations: 1     
    4. Lazure P, Sireci A, Subbiah V, Murray S, Groh? C, Sherman SI, Kelly E, Bubach P, P?loquin S. Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study. BMC Med Educ. 2023 Jun 05; 23(1):410. PMID: 37277734; PMCID: PMC10241144.
      Citations:    Fields:    Translation:Humans
    5. Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Sen S, Oliver JW, Banerjee K, Keam B, Capdevila J. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer. 2022 12 15; 128(24):4203-4212. PMID: 36259380; PMCID: PMC10092751.
      Citations: 4     Fields:    Translation:Humans
    6. Cabanillas ME, Busaidy NL, Sherman SI. Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World. Clin Cancer Res. 2022 Oct 03; 28(19):4164-4166. PMID: 35895318.
      Citations:    Fields:    
    7. Hofmann MC, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai SY, Zafereo M, Cabanillas ME. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocr Relat Cancer. 2022 11 01; 29(11):R173-R190. PMID: 35975971; PMCID: PMC9534048.
      Citations:    
    8. Kiyota N, Tahara M, Robinson B, Schlumberger M, Sherman SI, Leboulleux S, Lee EK, Suzuki T, Ren M, Fushimi K, Wirth LJ. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer. 2022 06 15; 128(12):2281-2287. PMID: 35380178; PMCID: PMC9325449.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Khalil M, Zafereo M, Gule-Monroe M, Sherman SI, Bell D. Non-functional water clear cell parathyroid carcinoma masquerading as medullary thyroid carcinoma. Ann Diagn Pathol. 2021 Oct; 54:151791. PMID: 34293707.
      Citations: 1     Fields:    Translation:Humans
    10. Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Bowles DW, Faoro L, Banerjee K, Oliver JW, Keam B, Vaisman F, Hoff AO, Hitre E, Hernando J, Capdevila J. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 08; 22(8):1126-1138. PMID: 34237250.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    11. Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, Bible KC, Robinson B, Rodien P, Godbert Y, Newbold K, Nutting C, Misir S, Xie R, Almonte A, Ye W, Cabanillas ME, De La Fouchardiere C. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol. 2021 07 20; 39(21):2359-2366. PMID: 33961488; PMCID: PMC8280094.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    12. Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, Dutcus CE, Xie R, Robinson B, Sherman S, Habra MA, Elisei R, Wirth LJ. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 2021 08; 31(8):1226-1234. PMID: 33637020; PMCID: PMC8377516.
      Citations: 7     Fields:    Translation:HumansCells
    13. Nies M, Vassilopoulou-Sellin R, Bassett RL, Yedururi S, Zafereo ME, Cabanillas ME, Sherman SI, Links TP, Waguespack SG. Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape. J Clin Endocrinol Metab. 2021 03 25; 106(4):e1683-e1697. PMID: 33382403; PMCID: PMC7993569.
      Citations: 8     Fields:    Translation:Humans
    14. Bagheri-Yarmand R, Dadu R, Ye L, Shiny Jebaraj Y, Martinez JA, Ma J, Tarapore RS, Allen JE, Sherman SI, Williams MD, Gagel RF. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021 04; 20(4):665-675. PMID: 33536187; PMCID: PMC9484041.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    15. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799. PMID: 33097651; PMCID: PMC7590373.
      Citations: 10     Translation:HumansCTClinical Trials
    16. Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG. Response to Ros?rio and Souza C?rtes re: "The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence". Thyroid. 2020 11; 30(11):1686-1687. PMID: 32484055.
      Citations:    Fields:    Translation:Humans
    17. Yin N, Sherman SI, Pak Y, Litofsky DR, Gianoukakis AG, National Thyroid Cancer Treatment Cooperative Study Group. The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence. Thyroid. 2020 10; 30(10):1490-1495. PMID: 32228151; PMCID: PMC7869880.
      Citations: 2     Fields:    Translation:Humans
    18. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328. PMID: 32437031; PMCID: PMC7262055.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    19. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986. PMID: 31309300.
      Citations: 6     Fields:    Translation:Humans
    20. Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484. PMID: 31186313; PMCID: PMC7038784.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    21. Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck. 2019 06; 41(6):1928-1934. PMID: 30758123; PMCID: PMC6542589.
      Citations: 6     Fields:    Translation:Humans
    22. Hurst Z, Liyanarachchi S, He H, Brock P, Sipos J, Nabhan F, Kebebew E, Green P, Cote GJ, Sherman S, Walker CJ, Chang YS, Xue S, Hollingsworth B, Li W, Genutis L, Menq E, de la Chapelle A, Jhiang SM. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid. 2019 04; 29(4):530-539. PMID: 30654714; PMCID: PMC6457887.
      Citations: 3     Fields:    Translation:Humans
    23. Sherman SI. EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA. Trans Am Clin Climatol Assoc. 2019; 130:255-265. PMID: 31516190; PMCID: PMC6736004.
      Citations:    Fields:    Translation:Humans
    24. Bagheri-Yarmand R, Sinha KM, Li L, Lu Y, Cote GJ, Sherman SI, Gagel RF. Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Mol Cancer Res. 2019 03; 17(3):751-760. PMID: 30552230; PMCID: PMC6902859.
      Citations: 7     Fields:    Translation:HumansCells
    25. Weitzman SP, Sherman SI. Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am. 2019 03; 48(1):253-268. PMID: 30717907.
      Citations: 6     Fields:    Translation:Humans
    26. Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy NL, Cabanillas ME, Dadu R, Sherman S, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier ND, Sturgis EM, Zafereo ME. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid. 2018 10; 28(10):1301-1310. PMID: 30141373.
      Citations: 35     Fields:    Translation:Humans
    27. Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab. 2018 10 01; 103(10):3698-3705. PMID: 30032208; PMCID: PMC6179172.
      Citations: 23     Fields:    Translation:Humans
    28. Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2. PMID: 32913986; PMCID: PMC7446411.
      Citations: 4     Fields:    
    29. Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 06 01; 124(11):2365-2372. PMID: 29656442.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    30. Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPAR? Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 04 01; 103(4):1277-1281. PMID: 29373711; PMCID: PMC6456920.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    31. Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402. PMID: 29427212; PMCID: PMC10013431.
      Citations: 6     Fields:    Translation:Humans
    32. Sherman SI, Tuttle RM, Daniels GH, LEADER Publication Committee on behalf of the LEADER Trial Investigators, Heged?s L, von Scholten BJ, Rasmussen S, Karsb?l JD. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 03; 41(3):620-622. PMID: 29279300.
      Citations: 12     Fields:    Translation:Humans
    33. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599. PMID: 28911154; PMCID: PMC5587058.
      Citations: 22     Fields:    Translation:Humans
    34. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421. PMID: 28275168; PMCID: PMC5354950.
      Citations: 13     Fields:    Translation:Humans
    35. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 04; 75:213-221. PMID: 28237867.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    36. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 04; 27(4):481-483. PMID: 28114862.
      Citations: 88     Fields:    Translation:Humans
    37. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128. PMID: 28155175; PMCID: PMC5368192.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    38. Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751. PMID: 27673361; PMCID: PMC5175438.
      Citations:    Fields:    Translation:Humans
    39. Xu JY, Murphy WA, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI, Milton DR. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877. PMID: 27662441; PMCID: PMC5155685.
      Citations: 7     Fields:    Translation:Humans
    40. Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467. PMID: 27575943; PMCID: PMC5095245.
      Citations: 11     Fields:    Translation:HumansCells
    41. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4103-4109. PMID: 27548104; PMCID: PMC5095235.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    42. Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS, Sch?ffski P. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864. PMID: 27525386.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    43. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82. PMID: 27460442; PMCID: PMC5532535.
      Citations: 110     Fields:    Translation:HumansCTClinical Trials
    44. Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. 2016; 90(6):339-46. PMID: 27207748; PMCID: PMC4909575.
      Citations: 17     Fields:    Translation:Humans
    45. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan; 26(1):1-133. PMID: 26462967; PMCID: PMC4739132.
      Citations: 3134     Fields:    Translation:Humans
    46. Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI. Follicular cell-derived thyroid cancer. Nat Rev Dis Primers. 2015 12 10; 1:15077. PMID: 27188261.
      Citations: 32     Fields:    Translation:HumansCells
    47. Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015 Dec; 106(12):1714-21. PMID: 26426092; PMCID: PMC4714672.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    48. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53. PMID: 26311725.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    49. McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct; 25(10):1097-105. PMID: 26203804; PMCID: PMC4589102.
      Citations: 9     Fields:    Translation:Humans
    50. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90. PMID: 26200040; PMCID: PMC4589264.
      Citations: 10     Fields:    Translation:Humans
    51. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep; 100(9):3270-9. PMID: 26171797; PMCID: PMC5393522.
      Citations: 50     Fields:    Translation:Humans
    52. Cabanillas ME, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW, Schlumberger M. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15; 121(16):2749-56. PMID: 25913680; PMCID: PMC4803478.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    53. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, Zhu J, Sherman SI, de las Heras B. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12; 372(7):621-30. PMID: 25671254.
      Citations: 516     Fields:    Translation:HumansCTClinical Trials
    54. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7. PMID: 25285888; PMCID: PMC4291160.
      Citations: 58     Fields:    Translation:Humans
    55. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81. PMID: 25353071; PMCID: PMC4283003.
      Citations: 48     Fields:    Translation:Humans
    56. Carhill AA, Litofsky DR, Sherman SI. Unique characteristics and outcomes of patients diagnosed with both primary thyroid and primary renal cell carcinoma. Endocr Pract. 2015 May; 21(5):461-7. PMID: 25536972.
      Citations: 1     Fields:    Translation:Humans
    57. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680. PMID: 25505208.
      Citations: 55     Fields:    Translation:Humans
    58. Perrin A, Sherman S, Pal S, Chua A, Gorritz M, Liu Z, Wang X, Culver K, Casciano R, Garrison LP. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ. 2015 Mar; 18(3):200-9. PMID: 25422989.
      Citations: 15     Fields:    Translation:Humans
    59. Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014 Oct; 24(10):1508-14. PMID: 25102375; PMCID: PMC4195402.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    60. Haddad R, Sherman SI, Shah JP, Wirth LJ. New frontiers and treatment paradigms for thyroid carcinoma. Clin Adv Hematol Oncol. 2014 Jul; 12(7 Suppl 14):3-21; quiz 22. PMID: 25768715.
      Citations: 3     Fields:    Translation:Humans
    61. Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106. PMID: 24617864; PMCID: PMC4080849.
      Citations: 13     Fields:    Translation:Humans
    62. Czerwonka L, Freeman J, McIver B, Randolph GW, Shah JP, Shaha AR, Sherman SI, Tuttle RM, Witterick IJ. Summary of proceedings of the second World Congress on Thyroid Cancer. Head Neck. 2014 Jul; 36(7):917-20. PMID: 24677329.
      Citations: 3     Fields:    Translation:Humans
    63. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Schlumberger MJ, DECISION investigators, de la Fouchardiere C, Pe?a C, Moln?r I. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26; 384(9940):319-28. PMID: 24768112; PMCID: PMC4366116.
      Citations: 452     Fields:    Translation:HumansCTClinical Trials
    64. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82. PMID: 24733667; PMCID: PMC4012968.
      Citations: 12     Fields:    Translation:Humans
    65. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94. PMID: 24628550; PMCID: PMC4037722.
      Citations: 35     Fields:    Translation:Humans
    66. McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI, The National Thyroid Cancer Treatment Cooperative Study Group. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014 Jan; 24(1):35-42. PMID: 23731273; PMCID: PMC3887423.
      Citations: 40     Fields:    Translation:Humans
    67. Schlumberger MJ, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI, Elisei R, M?ller SP, Sch?ffski P. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46. PMID: 24002501; PMCID: PMC4164813.
      Citations: 353     Fields:    Translation:HumansCTClinical Trials
    68. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013 Oct; 23(10):1277-83. PMID: 23489023; PMCID: PMC3967415.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    69. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. PMID: 23676418.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    70. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun; 34(3):439-55. PMID: 23575762; PMCID: PMC3660715.
      Citations: 37     Fields:    Translation:HumansAnimals
    71. Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol. 2013 Jul; 49(7):707-10. PMID: 23582411.
      Citations: 13     Fields:    Translation:Humans
    72. Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforov YE. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope. 2013 Apr; 123(4):1059-64. PMID: 23404751.
      Citations: 22     Fields:    Translation:Humans
    73. Sherman SI. The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer. Endocr Pract. 2013 Jan-Feb; 19(1):157-61. PMID: 23435044.
      Citations: 3     Fields:    Translation:Humans
    74. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42. PMID: 23185034; PMCID: PMC3537108.
      Citations: 30     Fields:    Translation:Humans
    75. Sherman SI. Emerging treatments in thyroid cancer. Clin Adv Hematol Oncol. 2012 Sep; 10(9):594-6. PMID: 23073125.
      Citations:    Fields:    Translation:Humans
    76. Cabanillas ME, Sherman SI. Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer. 2012 Apr; 19(2):C19-22. PMID: 22241721; PMCID: PMC4039023.
      Citations: 1     Fields:    Translation:Humans
    77. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid. 2012 Apr; 22(4):347-55. PMID: 22280230; PMCID: PMC3968956.
      Citations: 30     Fields:    Translation:Humans
    78. Clayman GL, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid. 2011 Dec; 21(12):1309-16. PMID: 22136266; PMCID: PMC3968954.
      Citations: 16     Fields:    Translation:Humans
    79. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011 Aug 11; 11:349. PMID: 21834960; PMCID: PMC3164634.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    80. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab. 2011 Jul; 96(7):2027-31. PMID: 21734003.
      Citations: 56     Fields:    Translation:Humans
    81. Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. Asia Pac J Clin Oncol. 2011 Jun; 7 Suppl 2:34-40. PMID: 21585706.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    82. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Ratain MJ, Salgia R, M?ller T. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. PMID: 21606412; PMCID: PMC3646303.
      Citations: 204     Fields:    Translation:HumansCTClinical Trials
    83. Di Lorenzo G, Casciano R, Malangone E, Buonerba C, Sherman S, Willet J, Wang X, Liu Z, De Placido S. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother. 2011 Jul; 12(10):1491-7. PMID: 21599551.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    84. Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol. 2011 Apr; 24 Suppl 2:S44-52. PMID: 21455200.
      Citations: 33     Fields:    
    85. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252; PMCID: PMC3070247.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    86. Moreno MA, Agarwal G, de Luna R, Siegel ER, Sherman SI, Edeiken-Monroe BS, Clayman GL. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2011 Feb; 137(2):157-62. PMID: 21339402.
      Citations: 13     Fields:    Translation:Humans
    87. Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin UH, Sherman SI, Santarpia L, Safe S. Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog. 2011 Sep; 50(9):655-67. PMID: 21268135; PMCID: PMC3128656.
      Citations: 14     Fields:    Translation:HumansCells
    88. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI, National Thyroid Cancer Treatment Cooperative Study Group. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010 Dec; 20(12):1423-4. PMID: 21054207.
      Citations: 26     Fields:    Translation:Humans
    89. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov; 8(11):1228-74. PMID: 21081783.
      Citations: 84     Fields:    Translation:Humans
    90. Bass MB, Sherman SI, Schlumberger MJ, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ, Patterson SD. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab. 2010 Nov; 95(11):5018-27. PMID: 20739388.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    91. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck. 2010 Jul; 32(7):829-36. PMID: 19885924.
      Citations: 33     Fields:    Translation:Humans
    92. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer. 2010 Jun 15; 116(12):2974-83. PMID: 20564403.
      Citations: 33     Fields:    Translation:HumansCells
    93. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol. 2010 Sep 01; 80(5):592-601. PMID: 20471374.
      Citations: 23     Fields:    Translation:Humans
    94. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010 Aug; 22(6):464-8. PMID: 20452757.
      Citations: 41     Fields:    Translation:Humans
    95. Sturgis EM, Sherman SI. Should papillary thyroid carcinoma be observed?: a word of caution. Arch Otolaryngol Head Neck Surg. 2010 May; 136(5):444-6. PMID: 20479372.
      Citations:    Fields:    Translation:Humans
    96. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, National Comprehensive Cancer Network. Medullary carcinoma. J Natl Compr Canc Netw. 2010 May; 8(5):512-30. PMID: 20495082.
      Citations: 24     Fields:    Translation:Humans
    97. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun; 95(6):2588-95. PMID: 20392874.
      Citations: 78     Fields:    Translation:Humans
    98. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010 Feb; 33(2):428-33. PMID: 20103558; PMCID: PMC2809297.
      Citations: 91     Fields:    Translation:Humans
    99. Ginsberg LE, Clayman GI, Edeiken-Monroe BS, Rohren E, Sherman SI. Not so fast on the thyroidectomy--response to Eloy, et al. AJNR Am J Neuroradiol. 2010 Feb; 31(2):E30; author reply E31. PMID: 20075083; PMCID: PMC7964136.
      Citations:    Fields:    Translation:Humans
    100. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec; 23(6):713-22. PMID: 19942148.
      Citations: 9     Fields:    Translation:Humans
    101. Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid. 2009 Dec; 19(12):1393-400. PMID: 20001721.
      Citations: 20     Fields:    Translation:HumansCells
    102. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8. PMID: 19903778; PMCID: PMC2784003.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    103. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroi, Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov; 19(11):1167-214. PMID: 19860577.
      Citations: 1910     Fields:    Translation:Humans
    104. Tulloch-Reid M, Skarulis MC, Sherman SI, Sarlis NJ, Santarpia L. Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy. Anticancer Res. 2009 Nov; 29(11):4665-71. PMID: 20032418; PMCID: PMC3109502.
      Citations:    Fields:    Translation:Humans
    105. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009 Nov; 94(11):4423-32. PMID: 19820016; PMCID: PMC2775645.
      Citations: 17     Fields:    Translation:Humans
    106. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009 Oct; 19(10):1043-8. PMID: 19772419.
      Citations: 54     Fields:    Translation:Humans
    107. Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck. 2009 Sep; 31(9):1152-63. PMID: 19360746.
      Citations: 20     Fields:    Translation:Humans
    108. Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr Pract. 2009 Sep-Oct; 15(6):605-11. PMID: 19546052.
      Citations: 4     Fields:    Translation:HumansAnimals
    109. Smith GL, Smith BD, Garden AS, Rosenthal DI, Sherman SI, Morrison WH, Schwartz DL, Weber RS, Buchholz TA. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck. 2009 Aug; 31(8):1031-8. PMID: 19360741.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    110. Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI, Schlumberger MJ. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10; 27(23):3794-801. PMID: 19564535.
      Citations: 108     Fields:    Translation:HumansCTClinical Trials
    111. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. 2009 May; 49(5):1563-70. PMID: 19399911; PMCID: PMC3715879.
      Citations: 56     Fields:    Translation:Humans
    112. Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid. 2009 Apr; 19(4):407-12. PMID: 19355831.
      Citations: 8     Fields:    Translation:Humans
    113. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab. 2009 May; 94(5):1493-9. PMID: 19258410.
      Citations: 27     Fields:    Translation:Humans
    114. Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck. 2009 Mar; 31(3):419-23. PMID: 18798312.
      Citations: 11     Fields:    Translation:Humans
    115. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol. 2009 Jun; 40(6):827-33. PMID: 19200582.
      Citations: 10     Fields:    Translation:Humans
    116. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1083-91. PMID: 19095376; PMCID: PMC2745400.
      Citations: 34     Fields:    Translation:Humans
    117. Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology. 2009; 76(1):59-68. PMID: 19052478.
      Citations: 19     Fields:    Translation:Humans
    118. Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S, Sarlis NJ. Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid. 2008 Aug; 18(8):901-5. PMID: 18651821.
      Citations: 3     Fields:    Translation:Humans
    119. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ, Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 03; 359(1):31-42. PMID: 18596272.
      Citations: 158     Fields:    Translation:HumansCTClinical Trials
    120. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, Clayman GL, Garden AS, Sherman SI. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. Head Neck. 2008 Jul; 30(7):883-8. PMID: 18213725.
      Citations: 19     Fields:    Translation:Humans
    121. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008 Jun; 37(2):511-24, xi. PMID: 18502340.
      Citations: 13     Fields:    Translation:Humans
    122. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008 Jan; 93(1):278-84. PMID: 17989125.
      Citations: 78     Fields:    Translation:HumansCells
    123. Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S. Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med. 2007 Nov-Dec; 11(6):1408-15. PMID: 18205710; PMCID: PMC4401302.
      Citations: 5     Fields:    Translation:HumansCells
    124. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008 Jan; 39(1):15-20. PMID: 17949783.
      Citations: 12     Fields:    Translation:HumansCells
    125. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM, National Comprehensive Cancer Network Thyroid Carcinoma Panel. Thyroid carcinoma. J Natl Compr Canc Netw. 2007 Jul; 5(6):568-621. PMID: 17623612.
      Citations: 21     Fields:    Translation:Humans
    126. Sherman SI. New approaches to therapy of thyroid malignancies. Clin Adv Hematol Oncol. 2007 Jul; 5(7):539-41. PMID: 17679927.
      Citations:    Fields:    Translation:Humans
    127. Sherman SI. Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma? Nat Clin Pract Endocrinol Metab. 2007 Jul; 3(7):510-1. PMID: 17519916.
      Citations:    Fields:    
    128. Sherman SI, Ladenson PW. Subacute thyroiditis causing thyroid storm. Thyroid. 2007 Mar; 17(3):283. PMID: 17381366.
      Citations: 3     Fields:    Translation:Humans
    129. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q. 2006 Dec; 22(4):231-8; discussion 239-40. PMID: 17146329.
      Citations: 44     Fields:    
    130. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006 Dec; 16(12):1229-42. PMID: 17199433.
      Citations: 169     Fields:    Translation:Humans
    131. Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007 Jan; 92(1):124-30. PMID: 17062760.
      Citations: 14     Fields:    Translation:Humans
    132. Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006 Jun; 91(6):2205-8. PMID: 16595600.
      Citations: 3     Fields:    Translation:Humans
    133. Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C, H?nscheid H. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006 Apr; 47(4):648-54. PMID: 16595499.
      Citations: 90     Fields:    Translation:Humans
    134. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jun; 91(6):2201-4. PMID: 16522694.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    135. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM, American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006 Feb; 16(2):109-42. PMID: 16420177.
      Citations: 446     Fields:    Translation:Humans
    136. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 Mar; 91(3):878-84. PMID: 16394083.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    137. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006 Mar; 91(3):926-32. PMID: 16384850.
      Citations: 91     Fields:    Translation:Humans
    138. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN, Society of Radiologists in Ultrasound. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005 Dec; 237(3):794-800. PMID: 16304103.
      Citations: 273     Fields:    Translation:Humans
    139. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005 Jun; 15(6):531-44. PMID: 16029119.
      Citations: 56     Fields:    Translation:Humans
    140. Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Ridge JA, Robbins R, Shah JP, Sisson JC, Thompson NW, National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw. 2005 May; 3(3):404-57. PMID: 16002006.
      Citations: 15     Fields:    Translation:Humans
    141. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8594-602. PMID: 15623643.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    142. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery. 2004 Dec; 136(6):1183-91. PMID: 15657574.
      Citations: 15     Fields:    Translation:Humans
    143. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26. PMID: 15287039.
      Citations: 69     Fields:    Translation:Humans
    144. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB. Surgical management of hereditary pheochromocytoma. J Am Coll Surg. 2004 Apr; 198(4):525-34; discussion 534-5. PMID: 15051000.
      Citations: 29     Fields:    Translation:Humans
    145. Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Vassillopoulou-Sellin R, Lee JE, Evans DB. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg. 2003 Dec; 186(6):702-9; discussion 709-10. PMID: 14672783.
      Citations: 62     Fields:    Translation:Humans
    146. Pederson LC, Shapiro SE, Fritsche HA, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE. Potential role for intraoperative gamma probe identification of normal parathyroid glands. Am J Surg. 2003 Dec; 186(6):711-7. PMID: 14672784.
      Citations: 4     Fields:    Translation:Humans
    147. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003 Dec; 134(6):890-9; discussion 899-901. PMID: 14668720.
      Citations: 10     Fields:    Translation:Humans
    148. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003 Dec; 134(6):946-54; discussion 954-5. PMID: 14668727.
      Citations: 120     Fields:    Translation:Humans
    149. Shepler TR, Sherman SI, Faustina MM, Busaidy NL, Ahmadi MA, Esmaeli B. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthalmic Plast Reconstr Surg. 2003 Nov; 19(6):479-81. PMID: 14625496.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    150. Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Reiners C, Luster M, H?nscheid H. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003 Oct; 30(10):1371-7. PMID: 12856155.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    151. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003 Apr; 138(4):409-16; discussion 416. PMID: 12686527.
      Citations: 40     Fields:    Translation:Humans
    152. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Sherman SI, Ordo?ez NG. Prognostic factors in patients with H?rthle cell neoplasms of the thyroid. Cancer. 2003 Mar 01; 97(5):1186-94. PMID: 12599224.
      Citations: 61     Fields:    Translation:Humans
    153. Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma. 2003 Mar; 3(4):249-52. PMID: 12672276.
      Citations: 16     Fields:    Translation:Humans
    154. Sherman SI. Thyroid carcinoma. Lancet. 2003 Feb 08; 361(9356):501-11. PMID: 12583960.
      Citations: 357     Fields:    Translation:Humans
    155. Royal RE, Delpassand ES, Shapiro SE, Fritsche HA, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery. 2002 Dec; 132(6):968-74; discussion 974-5. PMID: 12490843.
      Citations: 6     Fields:    Translation:Humans
    156. Ghori FY, Gutterman-Litofsky DR, Jamal A, Yeung SC, Arem R, Sherman SI. Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma. Thyroid. 2002 Nov; 12(11):1009-16. PMID: 12490079.
      Citations: 9     Fields:    Translation:Humans
    157. Sherman SI. Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2002 Sep; 87(9):4059-62. PMID: 12213844.
      Citations:    Fields:    Translation:Humans
    158. Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ, Evans DB. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002 Jun; 137(6):641-7. PMID: 12049533.
      Citations: 44     Fields:    Translation:Humans
    159. Sherman S, Udelsman R, Duh QY. How should you choose a thyroid surgeon? Thyroid. 2000 May; 10(5):439-41. PMID: 10884193.
      Citations:    Fields:    Translation:Humans
    160. Sherman SI. The management of metastatic differentiated thyroid carcinoma. Rev Endocr Metab Disord. 2000 Apr; 1(3):165-71. PMID: 11705002.
      Citations: 4     Fields:    Translation:Humans
    161. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999 Apr 08; 340(14):1075-9. PMID: 10194237.
      Citations: 52     Fields:    Translation:HumansCells
    162. Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol. 1999 Jan-Feb; 16(1):12-5. PMID: 9890734.
      Citations: 9     Fields:    Translation:Humans
    163. Sherman SI. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol. 1999 Jan-Feb; 16(1):30-3. PMID: 9890737.
      Citations:    Fields:    Translation:Humans
    164. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR. Outcome after treatment of high-risk papillary and non-H?rthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998 Oct 15; 129(8):622-7. PMID: 9786809.
      Citations: 23     Fields:    Translation:Humans
    165. Sherman SI. The risks of thyroidectomy: words of caution for referring physicians. J Gen Intern Med. 1998 Jan; 13(1):60-1. PMID: 9462498; PMCID: PMC1496889.
      Citations: 1     Fields:    Translation:Humans
    166. Lee JE, Evans DB, Sherman SI, Gagel RF. Evaluation of the incidental adrenal mass. Am J Med. 1997 Sep; 103(3):249-50. PMID: 9316558.
      Citations:    Fields:    Translation:Humans
    167. Sherman SI, Simonson L, Ladenson PW. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome? Am J Med. 1996 Aug; 101(2):192-8. PMID: 8757360.
      Citations: 5     Fields:    Translation:Humans
    168. Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994 Jun; 96(6):531-5. PMID: 8017451.
      Citations: 22     Fields:    Translation:Humans
    169. Sherman SI, Ladenson PW. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest. 1992 Mar; 15(3):185-90. PMID: 1624678.
      Citations: 9     Fields:    Translation:Humans
    170. Sherman SI, Ladenson PW. Percutaneous transluminal coronary angioplasty in hypothyroidism. Am J Med. 1991 Mar; 90(3):367-70. PMID: 2003519.
      Citations: 1     Fields:    Translation:Humans
    171. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine. The Lancet Oncology. 17:1272-1282.
    172. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 101:4103-4109.
    173. Overview of radioactive iodine-resistant differentiated thyroid cancer. Clinical Advances in Hematology and Oncology. 12:3-5.
    174. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 26:1744-1751.
    175. Why thyroid cancer?. Thyroid. 15:303-304.
    176. Surgical management of hereditary pheochromocytoma. Journal of the American College of Surgeons. 198:534-535.
    177. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 122:3856-3864.
    178. Erratum. Proceedings of the National Academy of Sciences of the United States of America. 89:8856.
    179. Molecular mechanisms in thyroid cancer biology. Clinical Advances in Hematology and Oncology. 12:10-13.
    180. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 26:1-133.
    181. Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis. Thyroid. 25:1097-1105.
    182. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer (The Journal of Clinical Endocrinology and Metabolism (2010) 95, (5018-5027)). Journal of Clinical Endocrinology and Metabolism. 96:252.
    183. Thyroid cancer. 295-310.
    184. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clinical Cancer Research. 22:44-53.
    185. Cancer disparities and thyroid carcinoma. Current Opinion in Endocrinology and Diabetes. 13:451-454.
    186. The author replies. New England Journal of Medicine. 359:2727.
    187. Carcimona of the thyroid. Seminars in Surgical Oncology. 16:3-4.
    188. Thyroid Cancer.
    189. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Archives of Dermatological Research. 1-9.
    190. Thyroid lymphoma. 615-619.
    191. Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life. Thyroid. 25:1085-1090.
    192. Detection and prognostic significance of circulating tumor cells in patients with metastatic thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 101:4461-4467.
    193. Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. Oncology (Switzerland). 90:339-346.
    194. Anaplastic carcinoma clinical aspects. 629-632.
    195. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). Journal of Clinical Endocrinology and Metabolism. 97:1399.
    196. Endocrine Complications of Head and Neck Surgery. 85-103.
    197. Erratum to "Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma" [Hum Pathol 40 (2009) 827-833] (DOI. Human Pathology. 40:1212.
    198. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 96:2286.
    199. Bone metastases and skeletal-related events in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 101:4871-4877.
    200. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Science. 106:1714-1721.
    201. Anaplastic carcinoma prognosis. 647-649.
    202. Efficacy and tolerability of vemurafenib in patients with BRAFV600E positive papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 100:E77-E81.
    SHERMAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (496)
    Explore
    _
    Co-Authors (96)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _